Table 3 Study population treatment
|  | AIH (n = 160) | PBC (n = 37) | PSC (n = 20) | Overlap syndrome (n = 48) |  |
|---|---|---|---|---|---|
Azathioprine | 151 (94.4%) | 6 (16.2%) | 5 (25.0%) | 41 (85.4%) | |
UDCA | 63 (39.4%) | 37 (100.0%) | 20 (100.0%) | 48 (100.0%) | |
Prednisolone | 145 (90.1%) | 1 (2.7%) | 1 (5.0%) | 44 (91.7%) | |
Mycophenolate Mofetil | 18 (11.2%) | 0 (0.0%) | 0 (0.0%) | 7 (14.6%) | |
Cyclosporine | 8 (5.0%) | 0 (0.0%) | 0 (0.0%) | 2 (4.2%) | |
Budesonide | 5 (3.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |